Fierce Pharma2d
Alnylam's Amvuttra wins key approval in ATTR-CM, teeing up showdown with Pfizer
Despite growing competition in the transthyretin amyloid cardiomyopathy (ATTR-CM) field, Alnylam is hoping its RNA ...
STAT1d
Alnylam enters the ATTR-CM drug race
Alnylam's Amvuttra enters ATTR-CM drug race, and Expedition Therapeutics seeks to bring Chinese drugs to the U.S.
pharmaphorum1d
Alnylam joins three-way contest in ATTR cardiomyopathy
Alnylam has the FDA approval it sought for Amvuttra in a form of cardiomyopathy associated with rare disease ATTR amyloidosis ...
ConsumerAffairs1d
FDA greenlights new drug to treat a serious type of heart disease
Heart disease patients now have another treatment option. The U.S. Food and Drug Administration has approved Alnylam ...
TCTMD1d
Vutrisiran, With the FDA’s Sign-off, Joins the Fray for ATTR-CM
Along with tafamidis and acoramidis, the drug is now the third for ATTR-CM, but it comes with a whopping price tag of ...
US FDA expands approval for Alnylam's drug to treat rare heart disease
U.S. Food and Drug Administration approved Alnylam's drug to treat a rare and deadly heart disease on Thursday, allowing the ...
Healio1d
FDA approves vutrisiran for ATTR amyloidosis with cardiomyopathy
Alnylam announced the FDA approval of its supplemental new drug application for vutrisiran, an RNA interfering small molecule ...
Alnylam Wins Expanded Heart Drug Approval, Challenging Pfizer
Alnylam Pharmaceuticals Inc. won expanded approval for a heart drug that could be the biggest boon yet for the 23-year-old ...